Abivax Shares Drop 9% at Close Following Q3 Results Announcement

Investor Caution Following Quarterly Accounts

The 9.12% decline in Abivax shares on Tuesday, December 16 reflects cautious investor reaction to the quarterly accounts published the day before. The closing price of 94.70 euros marks a return below the symbolic 100 euros barrier, after peaking at 120.80 euros on December 10. Over three months, the stock still shows an impressive gain of 32.08%, while the weekly performance has declined by 5.21%. These movements are part of a natural consolidation following the speculative surge in early December, fueled by rumors of a potential offer from Eli Lilly. The biotech company reported a net loss of 254.1 million euros for the first nine months of 2025, a significant increase from 136.9 million euros in the same period last year. This deterioration is mainly due to accelerated research and development expenses, which reached 133.4 million euros due to the advancement of phase 3 trials on ulcerative colitis and phase 2b trials on Crohn's disease. General and administrative expenses also increased from 16.5 million euros to 41.8 million euros, partly related to social charges resulting from the rise in the share price in the third quarter. The operating loss was 174.4 million euros compared to 130.2 million euros a year earlier. The financial result recorded a loss of 79.7 million euros, penalized by the increase in the fair value of convertible bonds and foreign exchange losses. Despite these figures, cash reserves stood at 589.7 million euros as of September 30, 2025, ensuring financial autonomy until the fourth quarter of 2027.

Analyst Upgrades Following Quarterly Results

In the wake of the quarterly results publication, Citizens raised its price target for Abivax from 114 euros to 131 euros on Tuesday, December 16, while maintaining its outperform market recommendation. This upward revision comes at a time when the stock is trading at 94.70 euros, suggesting a potential upside of 38% according to the analyst. This renewed confidence is based on the promising clinical prospects of obezafimod, whose phase 3 results presented in early November showed a significant improvement in the quality of life for patients with ulcerative colitis. Wolfe Research's stance, which began tracking in November with a target of 176 dollars and an outperform recommendation, also reflects the attractiveness of the case to analysts. However, investor reaction remains measured this Tuesday, with trading volumes limited to 0.15% of the capital, reflecting an expectation of more concrete catalyst elements. The upcoming publication of the 44-week maintenance trial results in the second quarter of 2026 will be a critical milestone to validate the commercial potential of the molecule. Meanwhile, persistent rumors of interest from major pharmaceutical companies, notably Eli Lilly, continue to fuel speculation about a possible merger or acquisition, although no official confirmation has been provided at this stage.

Technical Analysis and Market Sentiment

The price of 94.70 euros is slightly above the 50-day moving average at 92.34 euros, confirming the maintenance of an underlying bullish trend despite the day's decline. The more significant gap with the 200-day moving average at 43.91 euros reflects the extent of the revaluation since the beginning of the year, with an annual increase of 1,226%. The RSI at 46 is in a neutral zone, suggesting that the stock has absorbed some of the overheating observed in previous speculative sessions and has room for technical maneuver before reaching an oversold zone. This indicator confirms the absence of excessive bearish pressure and suggests potential short-term stabilization. The MACD displays a slightly negative histogram at -0.09, with a MACD line at 3.96 just below the signal line at 4.06, indicating a slowdown in very short-term momentum without invalidating the long-term dynamic. Bollinger Bands frame the stock between a support at 91.82 euros and a resistance at 117.52 euros, with the price currently in the lower part of this channel. This technical configuration suggests a consolidation phase in a market that remains structurally upward-oriented. The technical support threshold identified at 85.10 euros appears sufficiently distant not to pose an immediate threat, while the resistance at 115.80 euros represents a realistic technical target in case of a return of risk appetite. With a one-month volatility of 21.74% and a negative beta of -0.16, Abivax shows an almost total decorrelation with the CAC 40, explaining its ability to progress independently in an uncertain market environment.